Cagrilintide
Lyophilized Peptide Reference Material
This lyophilized peptide must be reconstituted with BAC water before use in research. Most customers forget to add it — don't get stuck waiting for a second order.
Add BAC WaterCagrilintide
Cagrilintide is a long-acting amylin analog currently among the most actively researched compounds in metabolic science. Originally developed as a synthetic analog of human amylin — a peptide co-secreted with insulin by pancreatic beta cells — Cagrilintide was engineered for extended receptor activity and enhanced stability compared to native amylin. It has been the subject of significant clinical and preclinical research, most notably in combination with semaglutide (under the investigational name CagriSema), where researchers have observed compounding effects on metabolic markers in animal and human trial models.Each vial contains 10mg of lyophilized Cagrilintide with pharmaceutical-grade mannitol as a lyoprotectant. Independently tested for purity and identity. Full COA available via our batch lookup tool.For laboratory research purposes only. Not for human consumption. Research use only.
Cagrilintide is a synthetic long-acting analog of amylin, a peptide hormone naturally produced and co-secreted alongside insulin by the beta cells of the pancreas. Native amylin plays a well-documented role in glucose regulation and energy homeostasis. Cagrilintide was engineered to replicate and extend amylin receptor activity with significantly improved pharmacokinetic stability, making it a more practical compound for research applications requiring sustained receptor engagement over extended observation periods.
Amylin is a 37 amino acid peptide hormone co-located with insulin in pancreatic beta cell granules. It is released in response to nutrient intake and acts on amylin receptors in the hypothalamus and brainstem — regions of the brain centrally involved in energy balance and metabolic regulation. Research has established amylin as a key modulator of gastric emptying rate, glucagon secretion, and satiety signaling in animal models. Cagrilintide’s design as a long-acting amylin analog makes it a valuable tool for studying these pathways over extended research timeframes.
Preclinical studies in rodent and non-human primate models have investigated Cagrilintide’s effects on body composition, food intake behavior, and metabolic markers including blood glucose and lipid profiles. Animal model research has documented statistically significant reductions in body weight and adipose tissue in subjects receiving Cagrilintide, with researchers noting sustained effects attributable to its extended half-life compared to native amylin. Studies have also examined its effects on gastric emptying rate and glucagon suppression in diabetic animal models.
CagriSema is the investigational name given to the combination of Cagrilintide and semaglutide — a GLP-1 receptor agonist — studied together in both preclinical and clinical research settings. The scientific rationale behind this combination is that amylin receptor pathways and GLP-1 receptor pathways operate through complementary but non-identical mechanisms in the hypothalamus. Research combining the two has investigated whether dual receptor engagement produces additive or synergistic effects on metabolic outcomes in animal and human trial models. This combination has attracted significant attention in metabolic research literature as a result.
Native amylin has a very short half-life and limited receptor binding duration, making it impractical for sustained research protocols. Cagrilintide was specifically engineered with fatty acid side chain modifications that enable albumin binding, dramatically extending its half-life and allowing once-weekly administration in clinical research settings. This structural modification is what makes Cagrilintide a significantly more versatile research compound than native amylin for laboratory applications.
Cagrilintide acts on amylin receptors, which are heterodimeric complexes composed of calcitonin receptors paired with receptor activity modifying proteins (RAMPs). These receptor complexes are expressed in key regions of the central nervous system including the hypothalamic arcuate nucleus and the area postrema — regions with established roles in energy homeostasis and metabolic regulation in published neuroscience literature.
Every batch is independently tested for purity and identity prior to shipping. Full COA data including purity percentage and testing methodology is available via our batch lookup tool using your batch number.
Cagrilintide arrives as a white to off-white lyophilized powder in a sterile sealed vial. Pharmaceutical-grade mannitol is included as a lyoprotectant, giving the powder visible bulk at the bottom of the vial. This is expected and normal.
In a cool, dry environment away from direct light and heat, lyophilized vials maintain compound integrity for approximately six months to one year. For extended preservation, deep freezer storage under stable conditions without repeated temperature cycling is appropriate. Published stability data for lyophilized peptides of this class suggests integrity can be maintained for several years under optimal frozen storage conditions — researchers should consult current literature for compound-specific stability data. Avoid repeated temperature cycling as it accelerates degradation regardless of storage temperature.
Once prepared for laboratory use, refrigerated storage is standard protocol. Research and stability studies indicate that prepared peptide solutions of this class typically maintain peak integrity for approximately 28 to 40 days under refrigerated conditions. Beyond this window researchers should account for potential degradation when designing experimental protocols.
For laboratory research purposes only.
Not for human consumption. Research use only.
